Recombinant Human Growth Hormone [EPC]

Recombinant Human Growth Hormone [EPC] was reported 21996 times

Drugs of the Recombinant Human Growth Hormone [EPC] class are most commonly taken among patients reporting these side effects:

# Drug class Count Frequency
0 FILARIASIS LYMPHATIC 9 0.8182
1 GLIONEURONAL TUMOUR 19 0.3519
2 CRANIOPHARYNGIOMA 101 0.3042
3 CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO DEVICE USE ERROR 690 0.2904
4 PERTHES DISEASE 10 0.2778
5 EPIPHYSIOLYSIS 62 0.2490
6 WRONG DEVICE USED 113 0.1723
7 INADVERTENT INJECTION AIR BUBBLE 21 0.1667
8 ADENOIDAL HYPERTROPHY 61 0.1614
9 DRUG ADMINISTERED IN WRONG DEVICE 153 0.1563
10 ANDROPAUSE 8 0.1538
11 MEDULLOBLASTOMA RECURRENT 16 0.1416
12 HEPATOBLASTOMA 13 0.1340
13 CEREBRAL SALT-WASTING SYNDROME 13 0.1313
14 PITUITARY TUMOUR RECURRENT 21 0.1207
15 EPIPHYSES PREMATURE FUSION 36 0.1188
16 GERM CELL CANCER 17 0.1172
17 GROWTH FAILURE 39 0.1134
18 PERFORMANCE ENHANCING PRODUCT USE 11 0.1111
19 NEUTROPHILIC PANNICULITIS 8 0.1111
20 MEDULLOBLASTOMA 16 0.1074
21 BLOOD GROWTH HORMONE DECREASED 21 0.1040
22 OSTEOCHONDROMA 12 0.1008
23 INSULIN-LIKE GROWTH FACTOR INCREASED 138 0.0967
24 SULPHAEMOGLOBINAEMIA 10 0.0862
25 GROWTH HORMONE DEFICIENCY 33 0.0831
26 ACROMEGALY 25 0.0789
27 GROWING PAINS 21 0.0775
28 PROGNATHISM 7 0.0745
29 GROWTH DISORDER 19 0.0704
30 IN VITRO FERTILISATION 12 0.0663
31 PRODUCT KNOWLEDGE DEFICIT 51 0.0652
32 ASTROCYTOMA, LOW GRADE 11 0.0647
33 GROWTH RETARDATION 173 0.0587
34 INSULIN-LIKE GROWTH FACTOR DECREASED 30 0.0567
35 PRIMARY HYPOTHYROIDISM 12 0.0566
36 INFANTILE HAEMANGIOMA 9 0.0556
37 HYPONATRAEMIC SEIZURE 14 0.0551
38 OSTEOCHONDROSIS 62 0.0534
39 CREUTZFELDT-JAKOB DISEASE 15 0.0519
40 PRIMARY HYPOGONADISM 8 0.0510
41 GROWTH ACCELERATED 11 0.0509
42 TENDON CALCIFICATION 9 0.0508
43 PRODUCT SUBSTITUTION 20 0.0495
44 EXPIRED DEVICE USED 163 0.0491
45 ADENOIDECTOMY 18 0.0464
46 PITUITARY TUMOUR BENIGN 72 0.0441
47 INCORRECT DOSE ADMINISTERED BY DEVICE 1155 0.0440
48 PRODUCT CONTAMINATION WITH BODY FLUID 9 0.0439
49 DEVICE MECHANICAL ISSUE 602 0.0439
50 SYRINGOMYELIA 12 0.0432
51 ASTROCYTOMA 17 0.0430
52 DEVICE BREAKAGE 1703 0.0419
53 PITUITARY TUMOUR 62 0.0416
54 INJECTION SITE DISCHARGE 222 0.0412
55 TOXIC CARDIOMYOPATHY 9 0.0402
56 DELAYED PUBERTY 10 0.0394
57 BONE DEVELOPMENT ABNORMAL 11 0.0386
58 ADENOIDAL DISORDER 10 0.0385
59 DEVICE LEAKAGE 1646 0.0379
60 MALOCCLUSION 11 0.0377
61 TEETHING 11 0.0367
62 SECONDARY HYPOGONADISM 12 0.0364
63 PROTEIN-LOSING GASTROENTEROPATHY 18 0.0362
64 BLOOD FOLLICLE STIMULATING HORMONE INCREASED 14 0.0358
65 HYPOTHALAMO-PITUITARY DISORDER 51 0.0350
66 OSTEOSARCOMA 13 0.0338
67 CHOLESTEATOMA 9 0.0323
68 TONSILLAR DISORDER 36 0.0320
69 AVULSION FRACTURE 9 0.0314
70 TONSILLAR HYPERTROPHY 49 0.0291
71 PITUITARY HAEMORRHAGE 9 0.0290
72 BLOOD INSULIN INCREASED 16 0.0290
73 ADRENOCORTICAL INSUFFICIENCY ACUTE 56 0.0287
74 PRECOCIOUS PUBERTY 16 0.0280
75 DEVICE DISPENSING ERROR 33 0.0279
76 CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 925 0.0274
77 CEREBRAL AMYLOID ANGIOPATHY 9 0.0273
78 ANAL INFECTION 7 0.0272
79 FOCAL NODULAR HYPERPLASIA 14 0.0269
80 ADMINISTRATION SITE BRUISE 9 0.0259
81 VENOUS HAEMORRHAGE 8 0.0258
82 OBSTRUCTIVE SLEEP APNOEA SYNDROME 36 0.0247
83 PHAEOCHROMOCYTOMA 16 0.0243
84 HYPOPITUITARISM 42 0.0241
85 GLUCOCORTICOID DEFICIENCY 10 0.0236
86 IDIOPATHIC INTRACRANIAL HYPERTENSION 51 0.0227
87 SCOLIOSIS 139 0.0224
88 BRAIN NEOPLASM 199 0.0216
89 BLOOD GROWTH HORMONE INCREASED 12 0.0215
90 MULTIPLE USE OF SINGLE-USE PRODUCT 119 0.0212
91 NEOPLASM RECURRENCE 71 0.0209
92 STUBBORNNESS 9 0.0209
93 ARNOLD-CHIARI MALFORMATION 19 0.0199
94 LIQUID PRODUCT PHYSICAL ISSUE 143 0.0196
95 APNOEIC ATTACK 11 0.0195
96 DIABETES INSIPIDUS 47 0.0195
97 FOCAL SEGMENTAL GLOMERULOSCLEROSIS 31 0.0193
98 NAIL BED DISORDER 8 0.0187
99 SNORING 70 0.0185
100 DEVICE DEFECTIVE 318 0.0183
101 TENOSYNOVITIS STENOSANS 10 0.0180
102 PRODUCT RECONSTITUTION QUALITY ISSUE 16 0.0179
103 POOR QUALITY DEVICE USED 179 0.0178
104 FEAR OF INJECTION 126 0.0176
105 HYPOGLYCAEMIC SEIZURE 16 0.0176
106 TOBACCO ABUSE 9 0.0169
107 KNEE DEFORMITY 25 0.0168
108 MOUTH BREATHING 7 0.0161
109 GLIOMA 10 0.0156
110 HYPERTROPHIC CARDIOMYOPATHY 24 0.0155
111 DEVICE PHYSICAL PROPERTY ISSUE 113 0.0147
112 HEPATIC NECROSIS 55 0.0146
113 INTRACRANIAL PRESSURE INCREASED 80 0.0143
114 NEEDLE ISSUE 417 0.0143
115 LACK OF INJECTION SITE ROTATION 24 0.0137
116 DEVICE USE ISSUE 237 0.0135
117 DEVICE USE CONFUSION 7 0.0134
118 BRAIN MIDLINE SHIFT 7 0.0133
119 CEREBRAL CYST 9 0.0131
120 LIMB ASYMMETRY 10 0.0130
121 MANUFACTURING PRODUCT SHIPPING ISSUE 7 0.0129
122 PAPILLOEDEMA 58 0.0128
123 LIMB DEFORMITY 20 0.0126
124 INSULIN RESISTANCE 26 0.0125
125 DEVELOPMENTAL HIP DYSPLASIA 10 0.0120
126 AMBLYOPIA 7 0.0118
127 DERMATILLOMANIA 7 0.0117
128 ENDOCRINE DISORDER 15 0.0117
129 PRODUCT AVAILABILITY ISSUE 258 0.0113
130 WRONG TECHNIQUE IN DEVICE USAGE PROCESS 521 0.0111
131 DEVICE ISSUE 1000 0.0111
132 VASOGENIC CEREBRAL OEDEMA 8 0.0111
133 OTITIS MEDIA ACUTE 8 0.0109
134 MYCOBACTERIUM CHELONAE INFECTION 8 0.0108
135 DRUG DOSE OMISSION BY DEVICE 848 0.0108
136 BREAST DISCOMFORT 11 0.0107
137 DEVICE OCCLUSION 147 0.0104
138 DEVICE LOOSENING 9 0.0104
139 BENIGN INTRACRANIAL HYPERTENSION 13 0.0104
140 POLYCYTHAEMIA 21 0.0102
141 SLEEP APNOEA SYNDROME 194 0.0102
142 ULNA FRACTURE 10 0.0101
143 DEVICE DELIVERY SYSTEM ISSUE 271 0.0099
144 INJECTION SITE EXTRAVASATION 122 0.0099
145 INJECTION SITE ATROPHY 16 0.0097
146 AUTISM SPECTRUM DISORDER 53 0.0096
147 SOLAR LENTIGO 9 0.0095
148 CRYPTORCHISM 10 0.0089
149 PULMONARY VALVE STENOSIS 7 0.0088
150 INCORRECT DRUG ADMINISTRATION RATE 37 0.0087
151 AORTIC VALVE DISEASE 14 0.0087
152 ADMINISTRATION SITE PAIN 10 0.0087
153 PRODUCT APPEARANCE CONFUSION 8 0.0087
154 UNDERWEIGHT 17 0.0086
155 HORMONE LEVEL ABNORMAL 42 0.0086
156 INCORRECT DOSAGE ADMINISTERED 41 0.0084
157 TONSILLECTOMY 14 0.0084
158 INJECTION SITE DISCOMFORT 88 0.0084
159 GLIOBLASTOMA MULTIFORME 7 0.0083
160 CONGENITAL CYSTIC KIDNEY DISEASE 7 0.0083
161 INJECTION SITE HAEMORRHAGE 659 0.0082
162 STRABISMUS 24 0.0082
163 GENITAL BURNING SENSATION 7 0.0081
164 ENDOCRINE OPHTHALMOPATHY 7 0.0081
165 HYPERPHAGIA 32 0.0080
166 INJECTION SITE BRUISING 637 0.0080
167 BLOOD TESTOSTERONE INCREASED 17 0.0079
168 VITH NERVE PARALYSIS 9 0.0079
169 TYPE 1 DIABETES MELLITUS 47 0.0078
170 APPENDIX DISORDER 11 0.0078
171 PRODUCT DEPOSIT 12 0.0077
172 OBLITERATIVE BRONCHIOLITIS 10 0.0076
173 GLIOBLASTOMA 13 0.0076
174 DRUG DELIVERY SYSTEM ISSUE 15 0.0076
175 TUMOUR NECROSIS 8 0.0076
176 LIPODYSTROPHY ACQUIRED 16 0.0075
177 EXCESSIVE EYE BLINKING 11 0.0074
178 SKIN STRIAE 11 0.0074
179 FEBRILE CONVULSION 9 0.0074
180 KIDNEY ENLARGEMENT 8 0.0073
181 INFERTILITY 11 0.0073
182 PRODUCT LEAKAGE 41 0.0073
183 OTITIS MEDIA 24 0.0073
184 DEVICE MALFUNCTION 506 0.0072
185 DEVICE USE ERROR 249 0.0072
186 SPINAL DEFORMITY 12 0.0071
187 HEMIANOPIA 7 0.0071
188 INTERCEPTED PRODUCT PRESCRIBING ERROR 9 0.0068
189 HYDROCEPHALUS 36 0.0066
190 JUVENILE IDIOPATHIC ARTHRITIS 16 0.0065
191 BLOOD PARATHYROID HORMONE INCREASED 19 0.0065
192 PAPILLARY THYROID CANCER 11 0.0063
193 INJECTION SITE PAIN 1940 0.0063
194 SARCOMA 7 0.0062
195 PRODUCT USE COMPLAINT 97 0.0062
196 DENGUE FEVER 14 0.0061
197 EXPOSURE VIA SKIN CONTACT 158 0.0061
198 GLUCOSE TOLERANCE IMPAIRED 36 0.0061
199 ELECTRIC SHOCK SENSATION 17 0.0061
200 EDUCATIONAL PROBLEM 10 0.0060
201 HYPOPHYSITIS 12 0.0060
202 VIITH NERVE PARALYSIS 20 0.0058
203 HEPATIC ENCEPHALOPATHY 54 0.0058
204 DEVICE DIFFICULT TO USE 382 0.0058
205 ADRENAL DISORDER 11 0.0057
206 HAEMATOCRIT INCREASED 13 0.0057
207 ENURESIS 23 0.0057
208 VENTRICULAR HYPERTROPHY 14 0.0056
209 TIBIA FRACTURE 26 0.0055
210 PRODUCT PREPARATION ISSUE 36 0.0055
211 INCORRECT DOSE ADMINISTERED 1233 0.0054
212 INJECTION SITE PARAESTHESIA 8 0.0052
213 APNOEA 40 0.0051
214 THERAPY CHANGE 50 0.0051
215 PRODUCT STORAGE ERROR 442 0.0050
216 HYPERNATRAEMIA 25 0.0050
217 PRODUCT SUPPLY ISSUE 35 0.0049
218 PRODUCT CONTAMINATION 17 0.0048
219 PRODUCT STORAGE ISSUE 18 0.0047
220 DEVICE CONNECTION ISSUE 10 0.0047
221 PRODUCT CONTAMINATION PHYSICAL 12 0.0047
222 MENOPAUSE 12 0.0047
223 TREATMENT DELAYED 8 0.0046
224 PRODUCT PRESCRIBING ERROR 105 0.0044
225 SCREAMING 28 0.0044
226 BRAIN OPERATION 10 0.0044
227 WOUND COMPLICATION 15 0.0044
228 MELANOCYTIC NAEVUS 19 0.0043
229 BRAIN NEOPLASM MALIGNANT 19 0.0042
230 URINE OUTPUT INCREASED 11 0.0042
231 INJECTION SITE SCAR 12 0.0042
232 INTRA-ABDOMINAL HAEMORRHAGE 10 0.0042
233 HUMERUS FRACTURE 20 0.0041
234 WRONG DOSE 10 0.0041
235 BREAST SWELLING 11 0.0041
236 PRODUCT TEMPERATURE EXCURSION ISSUE 21 0.0041
237 INJECTION SITE DISCOLOURATION 51 0.0041
238 SKIN ODOUR ABNORMAL 16 0.0041
239 PRODUCT PREPARATION ERROR 83 0.0040
240 PRODUCT DOSE OMISSION ISSUE 1165 0.0040
241 HAIR GROWTH ABNORMAL 27 0.0039
242 OESOPHAGEAL DISORDER 15 0.0039
243 PRODUCT ADMINISTRATION ERROR 78 0.0039
244 ASTHMATIC CRISIS 14 0.0038
245 HYPERTRICHOSIS 7 0.0038
246 BLOOD THYROID STIMULATING HORMONE DECREASED 17 0.0037
247 NEOPLASM 43 0.0037
248 DEREALISATION 8 0.0037
249 RECURRENT CANCER 15 0.0037
250 TONSILLITIS 19 0.0036
251 THERAPY INTERRUPTED 259 0.0036
252 PRODUCT CONTAINER ISSUE 31 0.0036
253 HIGH DENSITY LIPOPROTEIN DECREASED 12 0.0036
254 PRODUCT DISPENSING ERROR 78 0.0036
255 INFECTIOUS MONONUCLEOSIS 8 0.0036
256 DEVICE OPERATIONAL ISSUE 15 0.0035
257 GRANULOMA 12 0.0035
258 SYRINGE ISSUE 60 0.0034
259 POOR QUALITY PRODUCT ADMINISTERED 36 0.0034
260 HEPATIC NEOPLASM 11 0.0034
261 PRESCRIBED OVERDOSE 65 0.0034
262 HIP SURGERY 18 0.0033
263 LEARNING DISORDER 8 0.0033
264 CRYING 120 0.0033
265 GASTROENTERITIS 48 0.0033
266 THYROID NEOPLASM 9 0.0033
267 MULTIPLE-DRUG RESISTANCE 10 0.0032
268 ADRENAL INSUFFICIENCY 39 0.0032
269 APPENDICITIS 30 0.0032
270 TONGUE DISCOLOURATION 14 0.0032
271 OBESITY 51 0.0032
272 HEPATIC CIRRHOSIS 60 0.0032
273 BRAIN INJURY 32 0.0032
274 BLOOD PROLACTIN INCREASED 15 0.0032
275 VITAMIN D DEFICIENCY 31 0.0032
276 PRODUCT DISTRIBUTION ISSUE 29 0.0031
277 EPILEPSY 95 0.0031
278 FAILURE TO THRIVE 16 0.0031
279 MENINGIOMA 48 0.0031
280 BREAST ENLARGEMENT 10 0.0030
281 PRODUCT DISPENSING ISSUE 13 0.0030
282 LEFT VENTRICULAR HYPERTROPHY 13 0.0030
283 MYCOBACTERIUM AVIUM COMPLEX INFECTION 8 0.0030
284 INJECTION SITE VESICLES 18 0.0030
285 BLOOD SODIUM INCREASED 8 0.0030
286 PETIT MAL EPILEPSY 15 0.0029
287 TIC 16 0.0029
288 IMPULSIVE BEHAVIOUR 11 0.0029
289 THERAPY CESSATION 150 0.0029
290 INJECTION SITE MASS 108 0.0029
291 TALIPES 9 0.0029
292 ENERGY INCREASED 17 0.0029
293 ATTENTION DEFICIT HYPERACTIVITY DISORDER 12 0.0028
294 ACUTE LYMPHOCYTIC LEUKAEMIA 8 0.0028
295 TUMOUR HAEMORRHAGE 8 0.0028
296 GASTROINTESTINAL INFECTION 25 0.0028
297 RENAL TRANSPLANT 10 0.0028
298 HYPOGLYCAEMIA 134 0.0028
299 HEPATOTOXICITY 61 0.0027
300 STRIDOR 8 0.0027
301 LIPOMA 7 0.0027
302 DEVICE INFORMATION OUTPUT ISSUE 21 0.0027
303 DEVICE FAILURE 41 0.0027
304 AFFECTIVE DISORDER 21 0.0027
305 INCREASED APPETITE 51 0.0027
306 CRANIOCEREBRAL INJURY 8 0.0026
307 PRODUCT LABEL CONFUSION 15 0.0026
308 CEREBRAL DISORDER 19 0.0026
309 APPLICATION SITE HAEMORRHAGE 7 0.0026
310 BLOOD TEST ABNORMAL 36 0.0026
311 INJECTION SITE INJURY 14 0.0025
312 ACCIDENTAL EXPOSURE TO PRODUCT 257 0.0025
313 PARTIAL SEIZURES 13 0.0025
314 NEPHROTIC SYNDROME 17 0.0025
315 VIRAL INFECTION 82 0.0025
316 GOITRE 10 0.0024
317 PEPTIC ULCER 8 0.0024
318 METABOLIC DISORDER 14 0.0024
319 FLUID INTAKE REDUCED 12 0.0024
320 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 476 0.0023
321 MOOD ALTERED 64 0.0023
322 SEIZURE 271 0.0023
323 ATYPICAL PNEUMONIA 7 0.0023
324 VITAMIN D DECREASED 20 0.0023
325 CONCUSSION 18 0.0023
326 RHINOVIRUS INFECTION 9 0.0023
327 PERIORBITAL SWELLING 13 0.0023
328 PRODUCT COMMUNICATION ISSUE 20 0.0023
329 CEREBRAL ATROPHY 9 0.0023
330 INJECTION SITE HYPERSENSITIVITY 7 0.0022
331 PRODUCT DELIVERY MECHANISM ISSUE 12 0.0022
332 IRON DEFICIENCY 10 0.0022
333 INCORRECT ROUTE OF PRODUCT ADMINISTRATION 38 0.0022
334 INJURY ASSOCIATED WITH DEVICE 45 0.0022
335 EATING DISORDER 47 0.0022
336 INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS 12 0.0022
337 SPINAL STENOSIS 9 0.0022
338 EAR INFECTION 58 0.0022
339 PRODUCT ADMINISTRATION INTERRUPTED 17 0.0022
340 SUBARACHNOID HAEMORRHAGE 22 0.0022
341 THYROID DISORDER 33 0.0021
342 LEUKAEMIA 20 0.0021
343 PRESCRIPTION DRUG USED WITHOUT A PRESCRIPTION 13 0.0021
344 DRUG-INDUCED LIVER INJURY 66 0.0021
345 CARDIAC OPERATION 18 0.0021
346 ATRIOVENTRICULAR BLOCK COMPLETE 14 0.0021
347 ABNORMAL BEHAVIOUR 82 0.0021
348 UPPER LIMB FRACTURE 41 0.0021
349 SPINAL CORD COMPRESSION 8 0.0021
350 TESTIS CANCER 8 0.0020
351 INTENTIONAL DEVICE MISUSE 9 0.0020
352 STRESS FRACTURE 11 0.0020
353 BEHAVIOUR DISORDER 11 0.0020
354 SPINAL DISORDER 19 0.0020
355 PRODUCT ODOUR ABNORMAL 21 0.0020
356 VEIN DISORDER 10 0.0020
357 LOWER LIMB FRACTURE 38 0.0020
358 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 36 0.0020
359 APPENDICECTOMY 7 0.0020
360 SELF-MEDICATION 8 0.0019
361 HEPATOMEGALY 19 0.0019
362 PRE-EXISTING CONDITION IMPROVED 12 0.0019
363 SCRATCH 20 0.0019
364 HYPERTHYROIDISM 27 0.0019
365 OVERWEIGHT 10 0.0019
366 CARPAL TUNNEL SYNDROME 26 0.0019
367 LIGAMENT SPRAIN 18 0.0018
368 BLOOD ALKALINE PHOSPHATASE INCREASED 45 0.0018
369 INGUINAL HERNIA 11 0.0018
370 TENSION 11 0.0018
371 HAEMOGLOBIN INCREASED 8 0.0018
372 HYPOTHYROIDISM 56 0.0018
373 PRODUCT COLOUR ISSUE 9 0.0018
374 BLOOD DISORDER 14 0.0017
375 EAR DISORDER 8 0.0017
376 HEADACHE 1084 0.0017
377 DEVICE DEPLOYMENT ISSUE 22 0.0017
378 INTENTIONAL DOSE OMISSION 49 0.0017
379 AGGRESSION 86 0.0017
380 GASTROENTERITIS VIRAL 31 0.0017
381 CONTUSION 165 0.0017
382 GLOMERULAR FILTRATION RATE DECREASED 21 0.0017
383 HYPERURICAEMIA 7 0.0017
384 SUDDEN DEATH 18 0.0017
385 HYPERCALCAEMIA 21 0.0017
386 PRODUCT DOSE OMISSION IN ERROR 48 0.0017
387 BREAST PAIN 18 0.0017
388 FOOD ALLERGY 13 0.0017
389 UNDERDOSE 122 0.0017
390 GLYCOSYLATED HAEMOGLOBIN INCREASED 42 0.0017
391 BRAIN OEDEMA 21 0.0017
392 ELECTROLYTE IMBALANCE 19 0.0016
393 WRONG PRODUCT ADMINISTERED 11 0.0016
394 WEIGHT FLUCTUATION 17 0.0016
395 THIRST 29 0.0016
396 PRODUCT LABEL ISSUE 11 0.0016
397 CONCOMITANT DISEASE AGGRAVATED 10 0.0016
398 PIGMENTATION DISORDER 10 0.0016
399 JOINT DISLOCATION 17 0.0016
400 INJECTION SITE INFLAMMATION 8 0.0016
401 WRIST FRACTURE 19 0.0016
402 LIGAMENT RUPTURE 7 0.0016
403 PRODUCT DOSE OMISSION 103 0.0016
404 DISEASE RECURRENCE 75 0.0016
405 MALIGNANT MELANOMA 21 0.0016
406 PSYCHOMOTOR HYPERACTIVITY 26 0.0016
407 INJECTION SITE RASH 48 0.0016
408 MENINGITIS ASEPTIC 7 0.0016
409 OSTEONECROSIS 51 0.0016
410 DRUG EFFECT LESS THAN EXPECTED 23 0.0016
411 PERIORBITAL OEDEMA 8 0.0015
412 TENDON RUPTURE 19 0.0015
413 BLOOD THYROID STIMULATING HORMONE INCREASED 14 0.0015
414 NEOPLASM PROGRESSION 52 0.0015
415 BLOOD PRESSURE DIASTOLIC DECREASED 11 0.0015
416 ANKLE FRACTURE 23 0.0015
417 TYPE 2 DIABETES MELLITUS 50 0.0015
418 PALLOR 40 0.0015
419 HYPERSOMNIA 42 0.0015
420 INITIAL INSOMNIA 15 0.0015
421 LARYNGEAL OEDEMA 9 0.0015
422 THERAPEUTIC RESPONSE UNEXPECTED 65 0.0014
423 LYMPHOEDEMA 10 0.0014
424 DRUG ABUSE 120 0.0014
425 ACCIDENT 17 0.0014
426 SKIN HAEMORRHAGE 21 0.0014
427 HYPERVOLAEMIA 7 0.0014
428 THYROID CANCER 17 0.0014
429 HOSPITALISATION 217 0.0014
430 HAND FRACTURE 10 0.0014
431 OVARIAN CYST 14 0.0014
432 PRODUCT PHYSICAL ISSUE 28 0.0014
433 MOOD SWINGS 44 0.0014
434 RESPIRATORY SYNCYTIAL VIRUS INFECTION 12 0.0014
435 NERVOUSNESS 72 0.0014
436 BONE DISORDER 25 0.0014
437 SOMNAMBULISM 9 0.0014
438 PRODUCT PACKAGING ISSUE 13 0.0014
439 CORONAVIRUS INFECTION 9 0.0014
440 MASS 19 0.0014
441 ARTERIOSCLEROSIS CORONARY ARTERY 9 0.0014
442 MUSCLE DISORDER 11 0.0014
443 FLUID RETENTION 69 0.0014
444 FOOT DEFORMITY 15 0.0014
445 STEVENS-JOHNSON SYNDROME 30 0.0013
446 OBSTRUCTIVE AIRWAYS DISORDER 15 0.0013
447 BREAST MASS 9 0.0013
448 BLOOD SODIUM DECREASED 25 0.0013
449 COELIAC DISEASE 13 0.0013
450 FRACTURE 25 0.0013
451 EYE SWELLING 49 0.0013
452 INJECTION SITE SWELLING 100 0.0013
453 ANGER 44 0.0013
454 ILLNESS 134 0.0013
455 BRUXISM 7 0.0013
456 PULMONARY HYPERTENSION 27 0.0013
457 INJECTION SITE REACTION 89 0.0013
458 BLOOD IRON DECREASED 15 0.0013
459 HEAD INJURY 40 0.0013
460 IRRITABILITY 75 0.0012
461 INSURANCE ISSUE 19 0.0012
462 INJECTION SITE HAEMATOMA 18 0.0012
463 FRUSTRATION TOLERANCE DECREASED 10 0.0012
464 EXPIRED PRODUCT ADMINISTERED 41 0.0012
465 WEIGHT INCREASED 275 0.0012
466 REFUSAL OF TREATMENT BY PATIENT 8 0.0012
467 CORONARY ARTERY BYPASS 7 0.0012
468 LETHARGY 70 0.0012
469 BLOOD GLUCOSE DECREASED 58 0.0012
470 HYPERGLYCAEMIA 44 0.0012
471 MEDICATION ERROR 67 0.0012
472 ABORTION SPONTANEOUS 48 0.0012
473 PRODUCT PRESCRIBING ISSUE 26 0.0012
474 DIABETES MELLITUS INADEQUATE CONTROL 21 0.0012
475 AORTIC ANEURYSM 9 0.0012
476 ONYCHOCLASIS 8 0.0012
477 TRANSIENT ISCHAEMIC ATTACK 39 0.0012
478 BASAL CELL CARCINOMA 18 0.0012
479 CARDIOMYOPATHY 17 0.0011
480 SYNCOPE 113 0.0011
481 MENTAL DISORDER 49 0.0011
482 RHINITIS 9 0.0011
483 PRODUCT USE IN UNAPPROVED INDICATION 276 0.0011
484 PHARYNGITIS STREPTOCOCCAL 12 0.0011
485 FOOT FRACTURE 21 0.0011
486 INABILITY TO AFFORD MEDICATION 11 0.0011
487 MUSCLE ATROPHY 14 0.0011
488 ASPHYXIA 9 0.0011
489 PYREXIA 380 0.0011
490 INTENTIONAL PRODUCT MISUSE 96 0.0011
491 APPLICATION SITE PAIN 24 0.0011
492 LABORATORY TEST ABNORMAL 32 0.0011
493 TREATMENT NONCOMPLIANCE 59 0.0011
494 HUNGER 15 0.0011
495 ARTHRALGIA 447 0.0011
496 OCULAR DISCOMFORT 12 0.0011
497 FEMUR FRACTURE 33 0.0011
498 INJECTION SITE URTICARIA 26 0.0011
499 PAIN IN EXTREMITY 312 0.0011
500 SURGERY 62 0.0011
501 LOWER RESPIRATORY TRACT INFECTION 48 0.0011
502 COGNITIVE DISORDER 49 0.0010
503 INFLUENZA 117 0.0010
504 GASTRIC HAEMORRHAGE 12 0.0010
505 LYMPHOMA 16 0.0010
506 DRUG LEVEL INCREASED 17 0.0010
507 GROIN PAIN 9 0.0010
508 BLOOD TESTOSTERONE DECREASED 7 0.0010
509 PHARYNGEAL SWELLING 10 0.0010
510 PERIPHERAL SWELLING 157 0.0010
511 KNEE OPERATION 10 0.0010
512 MIGRAINE 97 0.0010
513 PHOTOPHOBIA 19 0.0010
514 HYPERLIPIDAEMIA 12 0.0010
515 DEVELOPMENTAL DELAY 9 0.0010
516 OBSESSIVE-COMPULSIVE DISORDER 8 0.0010
517 PRODUCT USE ISSUE 187 0.0010
518 NEOPLASM MALIGNANT 66 0.0010
519 HYPOTHERMIA 10 0.0010
520 RENAL DISORDER 46 0.0010
521 EXOSTOSIS 9 0.0010
522 DISTURBANCE IN ATTENTION 53 0.0010
523 EYE PAIN 55 0.0010
524 SPINAL OPERATION 12 0.0010
525 PERSONALITY CHANGE 9 0.0010
526 SWELLING FACE 63 0.0010
527 EMBOLISM 8 0.0010
528 BLOOD TRIGLYCERIDES INCREASED 17 0.0010
529 RESPIRATORY TRACT INFECTION 25 0.0010
530 INJECTION SITE ERYTHEMA 119 0.0010
531 BLINDNESS 39 0.0010
532 OFF LABEL USE 836 0.0010
533 PRODUCT COMPLAINT 24 0.0009
534 INTENTIONAL SELF-INJURY 19 0.0009
535 EMOTIONAL DISORDER 29 0.0009
536 COVID-19 165 0.0009
537 COLON CANCER 14 0.0009
538 CIRCULATORY COLLAPSE 16 0.0009
539 SPLENOMEGALY 11 0.0009
540 JOINT INJURY 20 0.0009
541 HYDRONEPHROSIS 7 0.0009
542 DIABETES MELLITUS 71 0.0009
543 DIZZINESS POSTURAL 9 0.0009
544 AUTOIMMUNE DISORDER 9 0.0009
545 PYELONEPHRITIS 8 0.0009
546 SEASONAL ALLERGY 13 0.0009
547 CONJUNCTIVITIS 17 0.0009
548 DIABETIC KETOACIDOSIS 22 0.0009
549 HIP ARTHROPLASTY 14 0.0009
550 IMMUNE SYSTEM DISORDER 12 0.0009
551 DEPRESSED MOOD 48 0.0009
552 PRODUCT QUALITY ISSUE 123 0.0009
553 MALAISE 397 0.0009
554 LYMPHADENOPATHY 32 0.0009
555 MEMORY IMPAIRMENT 124 0.0009
556 EYE HAEMORRHAGE 12 0.0009
557 ISCHAEMIC STROKE 16 0.0009
558 BLOOD UREA INCREASED 15 0.0009
559 NASOPHARYNGITIS 165 0.0009
560 NECK PAIN 50 0.0009
561 PROTEINURIA 17 0.0009
562 MALNUTRITION 10 0.0009
563 MYOSITIS 8 0.0009
564 HEAVY MENSTRUAL BLEEDING 8 0.0009
565 POOR QUALITY SLEEP 19 0.0009
566 OPTIC NEURITIS 8 0.0009
567 ACCIDENTAL OVERDOSE 32 0.0009
568 HYPONATRAEMIA 49 0.0009
569 SKIN DISORDER 29 0.0009
570 INJECTION SITE PRURITUS 58 0.0009
571 VOMITING 407 0.0009
572 INTRAOCULAR PRESSURE INCREASED 11 0.0009
573 HYPOPHAGIA 22 0.0009
574 UNRESPONSIVE TO STIMULI 22 0.0009
575 SLEEP DISORDER 60 0.0008
576 INJECTION SITE INDURATION 11 0.0008
577 CEREBRAL HAEMORRHAGE 30 0.0008
578 INCORRECT PRODUCT STORAGE 11 0.0008
579 BONE PAIN 49 0.0008
580 BRAIN FOG 13 0.0008
581 OSTEOMYELITIS 15 0.0008
582 NOCTURIA 10 0.0008
583 HYPERSENSITIVITY 151 0.0008
584 MUSCULOSKELETAL DISCOMFORT 14 0.0008
585 THROAT TIGHTNESS 22 0.0008
586 CYST 10 0.0008
587 HEPATIC STEATOSIS 15 0.0008
588 ACNE 61 0.0008
589 RHINORRHOEA 52 0.0008
590 LOSS OF CONSCIOUSNESS 103 0.0008
591 MUSCLE TIGHTNESS 13 0.0008
592 SKIN LESION 22 0.0008
593 ABDOMINAL PAIN UPPER 165 0.0008
594 PERIPHERAL COLDNESS 11 0.0008
595 JOINT STIFFNESS 21 0.0008
596 INTENTIONAL PRODUCT USE ISSUE 70 0.0008
597 PRODUCT SUBSTITUTION ISSUE 46 0.0008
598 SOMNOLENCE 160 0.0008
599 RHABDOMYOLYSIS 33 0.0008
600 HEAD DISCOMFORT 14 0.0008
601 EPISTAXIS 59 0.0008
602 DISCOMFORT 48 0.0008
603 GENERALISED TONIC-CLONIC SEIZURE 13 0.0008
604 INCORRECT PRODUCT ADMINISTRATION DURATION 17 0.0008
605 PRESYNCOPE 19 0.0008
606 DEVICE RELATED INFECTION 12 0.0008
607 GAIT INABILITY 26 0.0008
608 VISUAL IMPAIRMENT 96 0.0008
609 GASTROINTESTINAL CARCINOMA 7 0.0008
610 FEELING HOT 47 0.0008
611 INSOMNIA 204 0.0008
612 DEAFNESS 20 0.0008
613 PNEUMONIA BACTERIAL 7 0.0008
614 ANXIETY 216 0.0008
615 NERVE COMPRESSION 7 0.0008
616 SARS-COV-2 TEST POSITIVE 10 0.0008
617 BLOOD GLUCOSE INCREASED 141 0.0007
618 POLLAKIURIA 31 0.0007
619 ILL-DEFINED DISORDER 45 0.0007
620 IMMUNODEFICIENCY 11 0.0007
621 OROPHARYNGEAL PAIN 68 0.0007
622 CARDIOMEGALY 9 0.0007
623 AFFECT LABILITY 7 0.0007
624 GENERALISED OEDEMA 9 0.0007
625 TRANSAMINASES INCREASED 16 0.0007
626 NERVE INJURY 8 0.0007
627 HYPERTENSIVE CRISIS 8 0.0007
628 SKIN DISCOLOURATION 33 0.0007
629 FATIGUE 558 0.0007
630 DEMENTIA 20 0.0007
631 WEIGHT DECREASED 199 0.0007
632 FACE OEDEMA 12 0.0007
633 HEMIPARESIS 12 0.0007
634 ACUTE MYELOID LEUKAEMIA 11 0.0007
635 NERVOUS SYSTEM DISORDER 22 0.0007
636 BLOOD GLUCOSE ABNORMAL 13 0.0007
637 HYPOTONIA 7 0.0007
638 BRONCHOSPASM 10 0.0007
639 OEDEMA 38 0.0007
640 CHOLECYSTECTOMY 8 0.0007
641 BURNING SENSATION 49 0.0007
642 HYPERTENSION 148 0.0007
643 HAEMORRHAGE 73 0.0007
644 OXYGEN SATURATION DECREASED 39 0.0007
645 CONDITION AGGRAVATED 211 0.0007
646 PNEUMOTHORAX 11 0.0007
647 BLOOD URINE PRESENT 13 0.0007
648 HYPERHIDROSIS 88 0.0007
649 CONVULSION 39 0.0007
650 HELICOBACTER INFECTION 7 0.0007
651 ABDOMINAL PAIN 158 0.0007
652 FALL 225 0.0007
653 BACTERAEMIA 8 0.0007
654 PETECHIAE 7 0.0007
655 ROAD TRAFFIC ACCIDENT 28 0.0007
656 EYE DISORDER 22 0.0007
657 SNEEZING 15 0.0007
658 STAPHYLOCOCCAL INFECTION 22 0.0007
659 DRUG DOSE OMISSION 110 0.0007
660 BLOOD CHOLESTEROL INCREASED 31 0.0007
661 FEELING ABNORMAL 159 0.0007
662 KIDNEY INFECTION 13 0.0007
663 RENAL PAIN 7 0.0007
664 COAGULOPATHY 11 0.0007
665 OSTEOPENIA 10 0.0007
666 INFLAMMATION 34 0.0007
667 URTICARIA 110 0.0007
668 OSTEOPOROSIS 27 0.0007
669 HAEMATOMA 17 0.0007
670 NO THERAPEUTIC RESPONSE 8 0.0007
671 BODY HEIGHT DECREASED 7 0.0007
672 DRUG DISPENSING ERROR 10 0.0007
673 AGITATION 48 0.0007
674 IRRITABLE BOWEL SYNDROME 14 0.0007
675 RESPIRATORY DISTRESS 18 0.0007
676 PAIN 399 0.0006
677 MYALGIA 110 0.0006
678 FAECES DISCOLOURED 14 0.0006
679 MIDDLE INSOMNIA 12 0.0006
680 INFECTION 93 0.0006
681 FEEDING DISORDER 13 0.0006
682 PALPITATIONS 75 0.0006
683 OEDEMA PERIPHERAL 78 0.0006
684 DEHYDRATION 85 0.0006
685 BODY TEMPERATURE INCREASED 13 0.0006
686 DEPRESSED LEVEL OF CONSCIOUSNESS 25 0.0006
687 TACHYCARDIA 56 0.0006
688 PARALYSIS 9 0.0006
689 DECREASED APPETITE 146 0.0006
690 INJECTION SITE IRRITATION 8 0.0006
691 CORONARY ARTERY DISEASE 19 0.0006
692 POST PROCEDURAL COMPLICATION 12 0.0006
693 DRUG PRESCRIBING ERROR 12 0.0006
694 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 30 0.0006
695 DRUG INTERACTION 99 0.0006
696 ANAPHYLACTIC SHOCK 16 0.0006
697 ASTHMA 70 0.0006
698 RASH GENERALISED 16 0.0006
699 EAR PAIN 12 0.0006
700 BACK DISORDER 10 0.0006
701 DERMATITIS CONTACT 7 0.0006
702 JOINT SWELLING 74 0.0006
703 MICTURITION URGENCY 7 0.0006
704 TINNITUS 28 0.0006
705 PNEUMONIA 197 0.0006
706 HYPOACUSIS 26 0.0006
707 RESPIRATORY DISORDER 18 0.0006
708 AGEUSIA 15 0.0006
709 PNEUMONIA ASPIRATION 15 0.0006
710 SWELLING 56 0.0006
711 HAIR TEXTURE ABNORMAL 8 0.0006
712 VISION BLURRED 82 0.0006
713 GAIT DISTURBANCE 114 0.0006
714 INTERVERTEBRAL DISC PROTRUSION 13 0.0006
715 RED BLOOD CELL COUNT DECREASED 17 0.0006
716 DEPRESSION 135 0.0006
717 CANDIDA INFECTION 10 0.0006
718 TREMOR 98 0.0006
719 CEREBROVASCULAR ACCIDENT 100 0.0006
720 NEPHROLITHIASIS 27 0.0006
721 TOOTH DISORDER 13 0.0006
722 UPPER RESPIRATORY TRACT INFECTION 27 0.0006
723 MUSCULOSKELETAL DISORDER 11 0.0006
724 SINUSITIS 59 0.0006
725 DIZZINESS 287 0.0006
726 ASTHENIA 215 0.0006
727 HERNIA 11 0.0006
728 AMNESIA 37 0.0006
729 CONSTIPATION 124 0.0006
730 EXTRA DOSE ADMINISTERED 23 0.0006
731 BLOOD POTASSIUM DECREASED 17 0.0006
732 PHARYNGITIS 7 0.0006
733 METABOLIC ACIDOSIS 18 0.0006
734 RETCHING 12 0.0006
735 MATERNAL EXPOSURE DURING PREGNANCY 50 0.0006
736 POISONING 7 0.0006
737 BLOOD BILIRUBIN INCREASED 15 0.0006
738 MYELODYSPLASTIC SYNDROME 8 0.0006
739 CARDIOVASCULAR DISORDER 14 0.0006
740 BACK PAIN 128 0.0006
741 ERECTILE DYSFUNCTION 14 0.0005
742 URINARY INCONTINENCE 16 0.0005
743 MENTAL IMPAIRMENT 13 0.0005
744 CELLULITIS 27 0.0005
745 COUGH 150 0.0005
746 PROSTATE CANCER 43 0.0005
747 BEDRIDDEN 7 0.0005
748 VERTIGO 32 0.0005
749 HEART RATE INCREASED 52 0.0005
750 ANGINA PECTORIS 15 0.0005
751 SHOCK 12 0.0005
752 PANIC ATTACK 19 0.0005
753 HYPOAESTHESIA 78 0.0005
754 MUSCLE TWITCHING 12 0.0005
755 ANGIOEDEMA 23 0.0005
756 SPEECH DISORDER 27 0.0005
757 LUNG INFECTION 8 0.0005
758 IMPAIRED GASTRIC EMPTYING 7 0.0005
759 GINGIVAL BLEEDING 7 0.0005
760 CENTRAL NERVOUS SYSTEM LESION 7 0.0005
761 ABDOMINAL DISCOMFORT 85 0.0005
762 DISABILITY 10 0.0005
763 BLOOD PRESSURE INCREASED 77 0.0005
764 HALLUCINATION, AUDITORY 8 0.0005
765 FEELING COLD 14 0.0005
766 SENSORY DISTURBANCE 8 0.0005
767 BLINDNESS UNILATERAL 7 0.0005
768 NASAL CONGESTION 29 0.0005
769 DIALYSIS 7 0.0005
770 SUICIDAL IDEATION 45 0.0005
771 PANCREATITIS ACUTE 11 0.0005
772 IMPAIRED QUALITY OF LIFE 7 0.0005
773 PHOTOSENSITIVITY REACTION 8 0.0005
774 MUSCULAR WEAKNESS 55 0.0005
775 PERITONITIS 10 0.0005
776 CARDIAC DISORDER 45 0.0005
777 LIMB INJURY 13 0.0005
778 ALANINE AMINOTRANSFERASE INCREASED 29 0.0005
779 CHEST PAIN 87 0.0005
780 HEPATITIS 12 0.0005
781 THERAPEUTIC PRODUCT EFFECT DECREASED 21 0.0005
782 HAEMORRHAGE INTRACRANIAL 7 0.0005
783 GLAUCOMA 9 0.0005
784 HIP FRACTURE 15 0.0005
785 LACRIMATION INCREASED 14 0.0005
786 NIGHTMARE 16 0.0005
787 DIPLOPIA 12 0.0005
788 ECONOMIC PROBLEM 7 0.0005
789 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 83 0.0005
790 OVERDOSE 99 0.0005
791 SEPSIS 51 0.0005
792 MUSCULOSKELETAL STIFFNESS 40 0.0005
793 DRUG ADMINISTRATION ERROR 14 0.0005
794 DRUG INTOLERANCE 44 0.0005
795 PANCREATITIS 24 0.0005
796 GYNAECOMASTIA 14 0.0005
797 WITHDRAWAL SYNDROME 19 0.0005
798 NEURALGIA 11 0.0005
799 NAUSEA 358 0.0005
800 MUSCULOSKELETAL CHEST PAIN 7 0.0005
801 BLOOD CREATINE PHOSPHOKINASE INCREASED 13 0.0005
802 LIP SWELLING 15 0.0004
803 CEREBRAL INFARCTION 11 0.0004
804 INFLUENZA LIKE ILLNESS 37 0.0004
805 GALLBLADDER DISORDER 8 0.0004
806 GASTROINTESTINAL DISORDER 40 0.0004
807 FEAR 12 0.0004
808 COMA 21 0.0004
809 SCIATICA 7 0.0004
810 ALOPECIA 85 0.0004
811 BRONCHITIS 32 0.0004
812 PREMATURE BABY 13 0.0004
813 DEATH 372 0.0004
814 ABDOMINAL DISTENSION 45 0.0004
815 CONFUSIONAL STATE 69 0.0004
816 CHOLELITHIASIS 14 0.0004
817 TUBULOINTERSTITIAL NEPHRITIS 8 0.0004
818 RASH 186 0.0004
819 PARAESTHESIA 67 0.0004
820 HOT FLUSH 32 0.0004
821 UNEVALUABLE EVENT 32 0.0004
822 GASTRITIS 11 0.0004
823 HAEMATOCHEZIA 23 0.0004
824 DRUG INEFFECTIVE 542 0.0004
825 DYSSTASIA 12 0.0004
826 CHOKING 8 0.0004
827 SCAR 7 0.0004
828 MUSCLE SPASMS 75 0.0004
829 ACUTE MYOCARDIAL INFARCTION 12 0.0004
830 NIGHT SWEATS 13 0.0004
831 ORTHOSTATIC HYPOTENSION 7 0.0004
832 ECZEMA 21 0.0004
833 MUSCULOSKELETAL PAIN 21 0.0004
834 RASH MACULAR 14 0.0004
835 URINARY TRACT INFECTION 68 0.0004
836 BLOOD CREATININE INCREASED 26 0.0004
837 THROMBOSIS 32 0.0004
838 GENERAL PHYSICAL HEALTH DETERIORATION 46 0.0004
839 HYPOXIA 14 0.0004
840 COLD SWEAT 7 0.0004
841 INJECTION SITE WARMTH 8 0.0004
842 FLATULENCE 22 0.0004
843 CATARACT 23 0.0004
844 END STAGE RENAL DISEASE 7 0.0004
845 BONE DENSITY DECREASED 12 0.0004
846 DYSURIA 14 0.0004
847 COLITIS ULCERATIVE 17 0.0004
848 MOVEMENT DISORDER 12 0.0004
849 PSYCHOTIC DISORDER 11 0.0004
850 LOCALISED INFECTION 9 0.0004
851 INTESTINAL OBSTRUCTION 14 0.0004
852 PRURITUS GENERALISED 8 0.0004
853 NO ADVERSE EVENT 67 0.0004
854 CHRONIC KIDNEY DISEASE 28 0.0004
855 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 26 0.0004
856 RESPIRATORY ARREST 10 0.0004
857 MOBILITY DECREASED 26 0.0004
858 RENAL FAILURE 48 0.0004
859 VISUAL ACUITY REDUCED 12 0.0004
860 MYOCARDIAL INFARCTION 63 0.0004
861 URINARY RETENTION 12 0.0004
862 DYSPHONIA 21 0.0004
863 ARTHRITIS 28 0.0004
864 OSTEOARTHRITIS 15 0.0004
865 DISORIENTATION 14 0.0004
866 ANAEMIA 67 0.0004
867 BALANCE DISORDER 30 0.0003
868 ACUTE KIDNEY INJURY 53 0.0003
869 DIARRHOEA 223 0.0003
870 HALLUCINATION 26 0.0003
871 DYSKINESIA 14 0.0003
872 APPLICATION SITE ERYTHEMA 9 0.0003
873 LIVER DISORDER 15 0.0003
874 GASTROOESOPHAGEAL REFLUX DISEASE 27 0.0003
875 RENAL IMPAIRMENT 28 0.0003
876 CHEST DISCOMFORT 34 0.0003
877 BLOOD PRESSURE DECREASED 22 0.0003
878 CONTRAINDICATED PRODUCT ADMINISTERED 10 0.0003
879 STOMATITIS 20 0.0003
880 RESTLESSNESS 12 0.0003
881 INJURY 23 0.0003
882 CARDIAC ARREST 27 0.0003
883 LUNG DISORDER 16 0.0003
884 ABNORMAL DREAMS 9 0.0003
885 ENCEPHALOPATHY 8 0.0003
886 DIVERTICULITIS 9 0.0003
887 DRY SKIN 43 0.0003
888 HAEMATURIA 11 0.0003
889 MELAENA 7 0.0003
890 MULTIPLE ORGAN DYSFUNCTION SYNDROME 9 0.0003
891 ARRHYTHMIA 15 0.0003
892 OCULAR HYPERAEMIA 15 0.0003
893 HAEMATEMESIS 8 0.0003
894 FLUSHING 32 0.0003
895 RASH PRURITIC 17 0.0003
896 THERAPEUTIC RESPONSE DECREASED 19 0.0003
897 RASH PAPULAR 7 0.0003
898 PLEURAL EFFUSION 19 0.0003
899 DYSPNOEA 176 0.0003
900 CARDIO-RESPIRATORY ARREST 13 0.0003
901 IMPAIRED HEALING 10 0.0003
902 ANHEDONIA 8 0.0003
903 BLISTER 17 0.0003
904 RESPIRATORY FAILURE 22 0.0003
905 ASPARTATE AMINOTRANSFERASE INCREASED 16 0.0003
906 MENSTRUATION IRREGULAR 8 0.0003
907 HEPATIC FAILURE 9 0.0003
908 PAIN OF SKIN 8 0.0003
909 ERYTHEMA 61 0.0003
910 ADVERSE EVENT 27 0.0003
911 LIMB DISCOMFORT 9 0.0003
912 BREAST CANCER 27 0.0003
913 ADVERSE DRUG REACTION 26 0.0003
914 MENTAL STATUS CHANGES 8 0.0003
915 FIBROMYALGIA 7 0.0003
916 DISEASE PROGRESSION 34 0.0003
917 ABASIA 7 0.0003
918 SYSTEMIC LUPUS ERYTHEMATOSUS 10 0.0003
919 HYPOKALAEMIA 13 0.0003
920 CHILLS 33 0.0003
921 ABDOMINAL PAIN LOWER 7 0.0003
922 C-REACTIVE PROTEIN INCREASED 10 0.0003
923 PRODUCTIVE COUGH 13 0.0003
924 ASCITES 8 0.0003
925 FUNGAL INFECTION 9 0.0003
926 ARTHROPATHY 15 0.0003
927 PRURITUS 103 0.0003
928 LUNG NEOPLASM MALIGNANT 11 0.0003
929 INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION 19 0.0003
930 THERAPY NON-RESPONDER 12 0.0003
931 DYSARTHRIA 10 0.0003
932 DERMATITIS ATOPIC 14 0.0003
933 DYSPHAGIA 25 0.0003
934 CARDIAC FAILURE 21 0.0003
935 EYE IRRITATION 15 0.0003
936 HYPOTENSION 52 0.0003
937 ATRIAL FIBRILLATION 25 0.0003
938 HEART RATE DECREASED 9 0.0003
939 RECTAL HAEMORRHAGE 11 0.0003
940 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 14 0.0003
941 DYSPEPSIA 25 0.0003
942 ANAPHYLACTIC REACTION 14 0.0003
943 WHEEZING 15 0.0003
944 CYSTITIS 8 0.0003
945 SKIN EXFOLIATION 21 0.0002
946 PAIN IN JAW 7 0.0002
947 COLITIS 9 0.0002
948 HAEMOGLOBIN DECREASED 24 0.0002
949 THROMBOCYTOPENIA 26 0.0002
950 PULMONARY EMBOLISM 22 0.0002
951 PULMONARY OEDEMA 10 0.0002
952 FOETAL EXPOSURE DURING PREGNANCY 18 0.0002
953 SKIN IRRITATION 10 0.0002
954 SEPTIC SHOCK 9 0.0002
955 CARDIAC FAILURE CONGESTIVE 16 0.0002
956 DRY MOUTH 16 0.0002
957 HEPATIC ENZYME INCREASED 13 0.0002
958 NEUROPATHY PERIPHERAL 18 0.0002
959 BRADYCARDIA 10 0.0002
960 RASH ERYTHEMATOUS 9 0.0002
961 HEPATIC FUNCTION ABNORMAL 7 0.0002
962 NEUTROPENIA 25 0.0002
963 SUICIDE ATTEMPT 11 0.0002
964 LEUKOPENIA 9 0.0002
965 THROAT IRRITATION 8 0.0002
966 HERPES ZOSTER 10 0.0002
967 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 9 0.0002
968 INTENTIONAL OVERDOSE 11 0.0002
969 PLATELET COUNT DECREASED 18 0.0002
970 GASTROINTESTINAL HAEMORRHAGE 14 0.0002
971 PANCYTOPENIA 9 0.0002
972 DEVICE DISLOCATION 7 0.0002
973 DRY EYE 8 0.0002
974 DYSGEUSIA 11 0.0001
975 MULTIPLE SCLEROSIS RELAPSE 10 0.0001
976 WHITE BLOOD CELL COUNT DECREASED 15 0.0001
977 EMOTIONAL DISTRESS 16 0.0001
978 EXPOSURE DURING PREGNANCY 8 0.0001
979 RHEUMATOID ARTHRITIS 14 0.0001
980 BLADDER CANCER 7 0.0001
981 PSORIASIS 15 0.0001
982 TREATMENT FAILURE 9 0.0001
983 DRUG WITHDRAWAL SYNDROME 9 0.0001
984 TOXICITY TO VARIOUS AGENTS 8 0.0000
985 DRUG DEPENDENCE 7 0.0000